Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026

The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs

Novo Nordisk study exposes “hidden” inflammation driving cardio risk despite care

POSEIDON is among the largest global datasets to quantify this residual inflammatory burden

Lilly posts strong early clinical results for one-shot gene-editing cholesterol therapy

A one-shot gene-editing cholesterol therapy could soon be a reality

EMA backs conditional EU nod for Vijoice in rare life-threatening overgrowth disorder PROS

The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients

AstraZeneca to showcase cancer pipeline push at ASCO 2026

Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies

Lilly's retatrutide delivers 30% weight loss in Phase 3 TRIUMPH-1 trial

All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks

Boston Scientific invests $1.5 billion in MiRus for TAVR expansion

Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements

Philips unveils AI-powered SmartIQ to enhance coronary imaging

New CE-marked algorithm for the Azurion platform delivers improved image quality with over 50% lower radiation dose compared to the lowest settings on ClarityIQ

Novo Nordisk unveils breakthrough MASH data as ‘silent’ liver disease threatens 250 million

Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies